This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Lars Farde, MD; Fritz-Axel Wiesel, MD; Christer Halldin, PhD; Göran Sedvall, MD

Arch Gen Psychiatry. 1988;45(1):71-76.

Abstract
• Using positron emission tomography and the carbon 11—labeled ligand raclopride, central D2-dopamine receptor occupancy in the putamen was determined in psychiatric patients treated with clinical doses of psychoactive drugs. Receptor occupancy in drug-treated patients was defined as the percent reduction of specific carbon 11—raclopride binding in relation to the expected binding in the absence of drug treatment. Clinical treatment of schizophrenic patients with 11 chemically distinct antipsychotic drugs (including both classic and atypical neuroleptics such as clozapine) resulted in a 65% to 85% occupancy of D2-dopamine receptors. In a depressed patient treated with the tricyclic antidepressant nortriptyline, no occupancy was found. The time course for receptor occupancy and drug levels was followed after withdrawal of sulpiride or haloperidol. D2-dopamine receptor occupancy remained above 65% for many hours despite a substantial reduction of serum drug concentrations. In a sulpiride-treated patient, the dosage was reduced in four steps over a nine-week period and a curvilinear relationship was demonstrated between central D2-dopamine receptor occupancy and serum drug concentrations. The results demonstrate that clinical doses of all the currently used classes of antipsychotic drugs cause a substantial blockade of central D2-dopamine receptors in humans. This effect appears to be selective for the antipsychotics, since it was not induced by the antidepressant nortriptyline.

Author Affiliations
From the Department of Psychiatry and Psychology, Karolinska Institute (Drs Farde, Wiesel, and Sedvall), and the Karolinska Pharmacy, Karolinska Hospital (Dr Halldin), Stockholm.

Footnotes
Accepted for publication April 30, 1987.

Reprint requests to Department of Psychiatry and Psychology, Karolinska Hospital, PO Box 60500, S-104 01 Stockholm, Sweden (Dr Farde).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

In Vitro and in Vivo Evidence for a Lack of Interaction with Dopamine D2 Receptors by the Metabotropic Glutamate 2/3 Receptor Agonists 1S,2S,5R,6S-2-Aminobicyclo[3.1.0]hexane-2,6-bicaroxylate Monohydrate (LY354740) and (-)-2-Oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic Acid (LY379268)
Fell et al.
J. Pharmacol. Exp. Ther. 2009;331:1126-1136.
ABSTRACT | FULL TEXT  

Effects of the Antipsychotic Risperidone on Dopamine Synthesis in Human Brain Measured by Positron Emission Tomography with L-[{beta}-11C]DOPA: A Stabilizing Effect for Dopaminergic Neurotransmission?
Ito et al.
J. Neurosci. 2009;29:13730-13734.
ABSTRACT | FULL TEXT  

The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors: A Positron Emission Tomography Study With [11C]-(+)-PHNO
Graff-Guerrero et al.
Arch Gen Psychiatry 2009;66:606-615.
ABSTRACT | FULL TEXT  

"Breakthrough" Dopamine Supersensitivity during Ongoing Antipsychotic Treatment Leads to Treatment Failure over Time
Samaha et al.
J. Neurosci. 2007;27:2979-2986.
ABSTRACT | FULL TEXT  

Brain Receptor Imaging
Heiss and Herholz
JNM 2006;47:302-312.
ABSTRACT | FULL TEXT  

Biodistribution and Radiation Dosimetry of the Dopamine D2 Ligand 11C-Raclopride Determined from Human Whole-Body PET
Slifstein et al.
JNM 2006;47:313-319.
ABSTRACT | FULL TEXT  

Mechanism of New Antipsychotic Medications: Occupancy Is Not Just Antagonism
Grunder et al.
Arch Gen Psychiatry 2003;60:974-977.
ABSTRACT | FULL TEXT  

Is Regionally Selective D2/D3 Dopamine Occupancy Sufficient for Atypical Antipsychotic Effect? An In Vivo Quantitative [123I]Epidepride SPET Study of Amisulpride-Treated Patients
Bressan et al.
Am. J. Psychiatry 2003;160:1413-1420.
ABSTRACT | FULL TEXT  

Antipsychotic Dosing in Preclinical Models Is Often Unrepresentative of the Clinical Condition: A Suggested Solution Based on in Vivo Occupancy
Kapur et al.
J. Pharmacol. Exp. Ther. 2003;305:625-631.
ABSTRACT | FULL TEXT  

In Vivo Evidence for Dopamine-Mediated Internalization of D2-Receptors after Amphetamine: Differential Findings with [3H]Raclopride versus [3H]Spiperone
Sun et al.
Mol. Pharmacol. 2003;63:456-462.
ABSTRACT | FULL TEXT  

Psychosis as a State of Aberrant Salience: A Framework Linking Biology, Phenomenology, and Pharmacology in Schizophrenia
Kapur
Am. J. Psychiatry 2003;160:13-23.
ABSTRACT | FULL TEXT  

Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11]WAY-100635 and [11C]raclopride
Rabiner et al.
J Psychopharmacol 2002;16:195-199.
ABSTRACT  

The Role of Neuroimaging in Development of and Treatment With Antipsychotics
Verhoeff and Kapur
Journal of Pharmacy Practice 2001;14:332-340.
ABSTRACT  

No Support for Regional Selectivity in Clozapine-Treated Patients: A PET Study With [11C]Raclopride and [11C]FLB 457
Talvik et al.
Am. J. Psychiatry 2001;158:926-930.
ABSTRACT | FULL TEXT  

Rapid Release of Antipsychotic Drugs From Dopamine D2 Receptors: An Explanation for Low Receptor Occupancy and Early Clinical Relapse Upon Withdrawal of Clozapine or Quetiapine
Seeman and Tallerico
Am. J. Psychiatry 1999;156:876-884.
ABSTRACT | FULL TEXT  

Persistence of Haloperidol in Human Brain Tissue
Kornhuber et al.
Am. J. Psychiatry 1999;156:885-890.
ABSTRACT | FULL TEXT  

Delayed Normalization of Central D2 Dopamine Receptor Availability After Discontinuation of Haloperidol Decanoate: Preliminary Findings
Nyberg et al.
Arch Gen Psychiatry 1997;54:953-958.
ABSTRACT  

Clozapine Treatment of Schizophrenia
Pickar and Hsiao
JAMA 1995;274:981-983.
ABSTRACT  

Striatal D2 Dopamine Receptor Characteristics in Neuroleptic-Naive Schizophrenic Patients Studied With Positron Emission Tomography
Hietala et al.
Arch Gen Psychiatry 1994;51:116-123.
ABSTRACT  

Putting the 'A' in atypical: does {alpha}2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics?
Nutt
J Psychopharmacol 1994;8:193-195.
 

Positron-emitting radioligands for studies in vivo-probes for human psychopharmacology
Pike
J Psychopharmacol 1993;7:139-158.
 

Sleep in Schizophrenic Patients On and Off Haloperidol Therapy: Clinically Stable vs Relapsed Patients
Neylan et al.
Arch Gen Psychiatry 1992;49:643-649.
ABSTRACT  

Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine: Relation to Extrapyramidal Side Effects
Farde et al.
Arch Gen Psychiatry 1992;49:538-544.
ABSTRACT  

In Vivo Occupancy of Dopamine Receptors by Antipsychotic Drugs
Meltzer and Stockmeier
Arch Gen Psychiatry 1992;49:588-589.
ABSTRACT  

Haloperidol Blood Levels and Clinical Effects
Volavka et al.
Arch Gen Psychiatry 1992;49:354-361.
ABSTRACT  

D2 Dopamine Receptors in Neuroleptic-Naive Schizophrenic Patients: A Positron Emission Tomography Study With [11C]Raclopride
Farde et al.
Arch Gen Psychiatry 1990;47:213-219.
ABSTRACT  

Early psychopharmacology and the rise of modern brain research
Carlsson
J Psychopharmacol 1990;4:120-126.
 

Dopamine Receptor Occupancy and Plasma Haloperidol Levels
Wolkin et al.
Arch Gen Psychiatry 1989;46:482-483.
ABSTRACT